About PGxl

PGXL is an internationally recognized pioneer in the application of molecular diagnostics to pharmacogenetics and is the first laboratory to be CLIA-certified specifically for pharmacogenetics testing. The company was founded in 2005 by Dr. Roland Valdes, Jr., and Dr. Mark W. Linder, researchers who are among the worldwide thought leaders in the science underlying personalized medicine. Our scientists are leading the way in the incorporation of genetic information into the practice of medicine.

News

• PGXL Technologies to Add Single-Cell Sorting Technology

  We're adding Silicon Biosystems' DEPArrayTM to our already impressive set of capabilities. DEPArray is a technology that allows researchers to sort ...

• Patent No Longer Pending

  The United States Patent and Trade Office has issued patent number 8380539 for PerMIT, PGXL's decision support software. The application ...

• PGXL Announces National Distribution Deal

  PGXL Laboratory and Essential Molecular Testing Corporation have formed a long term distribution agreement.  The strategic alliance, PGXL Partners, gives ...

• PerMIT Works: The Age of Companion Informatics Begins

  Thrombosis and Haemostasis has published the study we alluded to earlier. The first release of hard data from ongoing trials ...